A randomized phase II study of topical triamcinolone as preemptive therapy for epidermal growth factor receptor inhibitor–induced papulopustular eruption—Preliminary results - 03/08/18
Marie Donaldson, BA, Northwestern University Feinberg School of Medicine; Linda Serrano, MD, Northwestern University Feinberg School of Medicine; Stephanie M. Rangel, PhD, Northwestern University Feinberg School of Medicine; Dennis P. West, PhD, Northwestern University Feinberg School of Medicine; Olga Lipiszko, BS, Northwestern University Feinberg School of Medicine; Alfred Rademaker, PhD, Robert H. Lurie Comprehensive Cancer Center of Northwestern University; Ahmad Amin, MD, Northwestern University Feinberg School of Medicine; Emily Keimig, MD, Northwestern University Feinberg School of Medicine; Jennifer N. Choi, MD, Northwestern University Feinberg School of Medicine
Le texte complet de cet article est disponible en PDF. Commercial support: None identified. |
Vol 79 - N° 3S1
P. AB20 - septembre 2018 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?